These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 35923801)

  • 1. Mucormycosis in the COVID-19 Environment: A Multifaceted Complication.
    Sharma R; Kumar P; Rauf A; Chaudhary A; Prajapati PK; Emran TB; Gonçalves Lima CM; Conte-Junior CA
    Front Cell Infect Microbiol; 2022; 12():937481. PubMed ID: 35923801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucormycosis in COVID-19 patients: predisposing factors, prevention and management.
    Rudrabhatla PK; Reghukumar A; Thomas SV
    Acta Neurol Belg; 2022 Apr; 122(2):273-280. PubMed ID: 34820787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India.
    Patel A; Agarwal R; Rudramurthy SM; Shevkani M; Xess I; Sharma R; Savio J; Sethuraman N; Madan S; Shastri P; Thangaraju D; Marak R; Tadepalli K; Savaj P; Sunavala A; Gupta N; Singhal T; Muthu V; Chakrabarti A;
    Emerg Infect Dis; 2021 Sep; 27(9):2349-2359. PubMed ID: 34087089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India.
    Dravid A; Kashiva R; Khan Z; Bande B; Memon D; Kodre A; Mane M; Pawar V; Patil D; Kalyani S; Raut P; Bapte M; Saldanha C; Chandak D; Patil T; Reddy S; Bhayani K; Suresh L; Dillibabu V; Srivastava S; Khandelwal S; More S; Shakeel A; Pawar M; Nande P; Harshe A; Kadam S; Hallikar S; Kamal N; Andrabi D; Bodhale S; Raut A; Chandrashekhar S; Raman C; Mahajan U; Joshi G; Mane D
    Mycoses; 2022 May; 65(5):526-540. PubMed ID: 35212032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronavirus disease-associated mucormycosis (CAM): A case control study during the outbreak in India.
    Wasiq M; K R; Gn A
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Serum Iron Studies in COVID Associated Mucormycosis with Stage of the Disease.
    Rao C; R M
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 associated mucormycosis - An emerging threat.
    Chao CM; Lai CC; Yu WL
    J Microbiol Immunol Infect; 2022 Apr; 55(2):183-190. PubMed ID: 35074291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach.
    Azhar A; Khan WH; Khan PA; Alhosaini K; Owais M; Ahmad A
    J Infect Public Health; 2022 Apr; 15(4):466-479. PubMed ID: 35216920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World.
    Muthu V; Rudramurthy SM; Chakrabarti A; Agarwal R
    Mycopathologia; 2021 Dec; 186(6):739-754. PubMed ID: 34414555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucormycosis, past and present: a comprehensive review.
    Gupta I; Baranwal P; Singh G; Gupta V
    Future Microbiol; 2023 Feb; 18():217-234. PubMed ID: 36970978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19-associated mucormycosis, diabetes and steroid therapy: Experience in a single centre in Western Mexico.
    Guzmán-Castro S; Chora-Hernandez LD; Trujillo-Alonso G; Calvo-Villalobos I; Sanchez-Rangel A; Ferrer-Alpuin E; Ruiz-Jimenez M; Corzo-Leon DE
    Mycoses; 2022 Jan; 65(1):65-70. PubMed ID: 34674319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucormycosis an added burden to Covid-19 Patients: An in-depth systematic review.
    Shah NN; Khan Z; Ahad H; Elderdery AY; Alomary MN; Atwah B; Alhindi Z; Alsugoor MH; Elkhalifa AME; Nabi S; Bashir SM; Yaqub T; Rather GA; Ansari MA
    J Infect Public Health; 2022 Nov; 15(11):1299-1314. PubMed ID: 36279686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [COVID-19 associated mucormycosis. A case in Argentina].
    Aparicio M; Tuculet B; Rivolier MG; Forte A; Vila A
    Medicina (B Aires); 2022; 82(2):304-307. PubMed ID: 35417397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors and outcomes of COVID associated mucormycosis in kidney transplant recipients.
    Bansal SB; Rana A; Babras M; Yadav D; Jha P; Jain M; Sethi SK
    Transpl Infect Dis; 2022 Apr; 24(2):e13777. PubMed ID: 34932870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Outcome of Coronavirus Disease-associated Mucormycosis: 1-year Follow-up Study from India.
    Agrawal P; Singh AP; Chakotiya PS; Kumar V; Gautam A; Kumar D
    J Assoc Physicians India; 2024 Jun; 72(6):44-48. PubMed ID: 38881134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for COVID-19 associated mucormycosis in India: A case control study.
    Patel AK; Bakshi H; Shah K; Patel S; Patel T; Patel K; Patel KK
    Med Mycol; 2022 Jul; 60(7):. PubMed ID: 35709394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 and mucormycosis superinfection: the perfect storm.
    Al-Tawfiq JA; Alhumaid S; Alshukairi AN; Temsah MH; Barry M; Al Mutair A; Rabaan AA; Al-Omari A; Tirupathi R; AlQahtani M; AlBahrani S; Dhama K
    Infection; 2021 Oct; 49(5):833-853. PubMed ID: 34302291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 associated multisystemic mucormycosis from India: a multicentric retrospective study on clinical profile, predisposing factors, cumulative mortality and factors affecting outcome.
    Sahu M; Shah M; Mallela VR; Kola VR; Boorugu HK; Punjani AAR; Kumar RV; Kumar S; Manusrut M; Kumar SCR; Rathod R; Babu DM; Gonuguntla HK; Yedlapati GK; Mallu GR; Reddy YS; Reddy VV; Alwala S; Bongu VK; Kamalesh A; Kumar RNK; Jaishetwar GS; Bagapally RS; Srinivas JS; Balasubramaniam A; Rajagopalan BK; Pullikanti B; Prakasham SP; Nimmala P; Nagaraju B; Sahoo PR;
    Infection; 2023 Apr; 51(2):407-416. PubMed ID: 35922704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, cumulative mortality and factors affecting the outcome of COVID-19-associated mucormycosis from Western India.
    Vare AA; Yellambkar S; Farheen A; Nandedkar V; Bhombe SS; Shah R
    Indian J Ophthalmol; 2021 Dec; 69(12):3678-3683. PubMed ID: 34827021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes, COVID 19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center in Western India.
    Mishra Y; Prashar M; Sharma D; Akash ; Kumar VP; Tilak TVSVGK
    Diabetes Metab Syndr; 2021; 15(4):102196. PubMed ID: 34246939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.